Skip to main content
market.news โ€” Markets without borders
Biotech Sector

Biotech Sector News

Companies developing drugs, therapies, and diagnostics using biological processes.

What is Biotech Sector?

Biotech firms range from early-stage clinical-trial companies (binary outcomes โ€” drugs either work or don't) to large commercial-stage names (Amgen, Gilead, Vertex, Regeneron). Big Pharma (Pfizer, Merck, Novartis, Roche) increasingly acquires biotechs for pipeline. Indian biotech (Biocon) and emerging-market biosimilar makers add global dimension.

Why it matters for investors

Biotech is high-risk, high-reward โ€” successful drug approvals can create multi-bagger returns, while trial failures cause stocks to fall 50%+ overnight. The sector is rate-sensitive (long-duration cash flows) and policy-sensitive (drug pricing, FDA decisions, Medicare negotiations).

Frequently asked questions

How do I evaluate biotech stocks?

For pre-revenue: cash runway, pipeline strength, trial readouts. For commercial: revenue growth, patent cliffs, pipeline-replacement quality.

Why is biotech rate-sensitive?

Drug development has multi-year (often 10+) cash flows. Higher discount rates dramatically reduce present value, hitting biotech valuations harder than mature sectors.

๐Ÿ‡จ๐Ÿ‡ฆ Canada

Everest Clinical Research Acquires Firma's Biometrics Unit to Expand Global Data Science Capabilities

Everest Clinical Research, backed by Arlington Capital Partners, acquired the Biometrics and Data Services unit of Firma Clinical Research

Sep 17, 2026

๐Ÿ‡จ๐Ÿ‡ฆ Canada

Optimi Health Launches Phase 3 MDMA Therapy Trial for PTSD โ€” 100 Veterans and Frontline Workers

Optimi Health (OPTH) launches Phase 3 trial of MDMA-assisted therapy for PTSD in up to 100 veterans and frontline workers

Sep 17, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

TME Pharma Surges 20%+ on CEO Progress Statement, Phase 2 Glioma Trial on Track

TME Pharma (ALTME) shares surged over 20% after CEO statement on business and clinical progress

Sep 17, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Orchestra BioMed Receives $6.1 Million Milestone Payment from Haemonetics Acquisition of Vivasure Medical

Orchestra BioMed (OBIO) received a $6.1 million milestone payment tied to Haemonetics Corporation's (HAE) acquisition of Vivasure Medical

Sep 16, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Bio-Techne Supplements Merger Proxy Amid Shareholder Lawsuit as Merck KGaA Vote Nears

Bio-Techne faces a merger lawsuit and voluntarily supplemented proxy disclosures including Goldman Sachs valuation analyses ahead of its shareholder vote on acquisition by Merck KGaA.

Sep 15, 2026

๐Ÿ‡ฐ๐Ÿ‡ท South Korea

Korea: ์ œ๋„จ์…€ Insider Trading Allegations Resurface Amid Minister Nomination Controversy

Allegations of insider trading in ์ œ๋„จ์…€ (Genencell) shares resurfaced linked to Justice Minister nominee Kim Seungwon

Sep 15, 2026

๐Ÿ‡ฆ๐Ÿ‡บ Australia

CSL Shares Up 25%: Can Biotech Earnings Catch Up to the Premium Valuation?

CSL Limited (ASX: CSL) shares have surged over 25%, raising the question of whether earnings can justify the move

Sep 14, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Impact BioMedical Executes Reverse Stock Split to Advance Nasdaq-Listed Merger

Impact BioMedical announced a reverse stock split to maintain listing compliance ahead of a planned merger, a common pre-deal capital structure adjustment for small-cap biotech companies.

Sep 14, 2026

Us

Xenon's Epilepsy Drug Win Took XENE to $59 โ€” Now Depression Must Take It Further

Xenon Pharmaceuticals' Phase 3 trial of azetukalner delivered a 53% reduction in focal seizures, bringing the FDA filing for the epilepsy indication within sight. Now analysts say the next re-rating catalyst must come from the depression indication pipeline.

Sep 14, 2026

๐Ÿ‡จ๐Ÿ‡ฆ Canada

Definium Therapeutics Reveals Phase 3 Anxiety Trial Results in Monday Webcast

Definium Therapeutics will host a live webcast Monday at 8am EDT to discuss topline results from its Phase 3 Panorama Study in Generalized Anxiety Disorder.

Sep 14, 2026

AXSM

Axsome Therapeutics Shares Jump Nearly 6% as Auvelity Antidepressant Prescriptions Surge

Axsome Therapeutics (AXSM) shares rose nearly 6% in a single session following data showing a surge in prescriptions for Auvelity, the company's innovative antidepressant, signaling strong early commercial momentum for the drug.

Sep 12, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

XORTX Therapeutics Surges 31% as Clinical and Commercial Manufacturing of XORLO Begins

XORTX Therapeutics (XRTX) shares surged 31% after announcing clinical and commercial manufacturing start for XORLO

Sep 12, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Tyra Biosciences Plunges 33% After Phase II Trial Misses Market Expectations

Tyra Biosciences (TYRA) shares fell 33% after Phase II clinical trial results failed to meet market expectations.

Sep 10, 2026

๐Ÿ‡จ๐Ÿ‡ณ China

Hong Kong Targets Biomedicine Hub Status in Debut Five-Year Plan as GSK Signals Greater Bay Area Expansion

Hong Kong is set to place biomedicine at the centre of its first-ever five-year economic plan, while GSK reaffirms interest in Greater Bay Area biotech expansion at BIOHK conference.

Sep 10, 2026

๐Ÿ‡ฆ๐Ÿ‡บ Australia

EchoIQ ASX Shares Crash 48% as AI Medtech Valuation Fragility Exposed

EchoIQ shares crashed 48% on the ASX, exposing the extreme valuation fragility of pre-revenue AI healthcare companies when growth narratives face market scrutiny.

Sep 9, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Novartis Sinks 13.5% as Del-Desiran Fails Phase Trial, Putting $12B Avidity Deal Under Scrutiny

Novartis shares fell 13.5% after del-desiran, the lead drug in its $12 billion Avidity acquisition, missed its primary endpoint

Sep 9, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Roivant and Pharvaris Surge to Record Highs on Blowout Rare Disease Trial Results

Roivant Sciences and Pharvaris both hit record highs on clinical trial wins in lung disease and hereditary angioedema.

Sep 9, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Dyne Therapeutics Shares Fall 28% After Novartis Phase III Trial Disappointment in Gene Therapy

Dyne Therapeutics (DYN) stock fell approximately 28% following adverse clinical trial data

Sep 9, 2026

๐ŸŒ Global

Insilico Medicine's AI-Designed Lung Drug Reverses Aging Markers in Clinical Study Milestone

Insilico Medicine's AI-discovered lung drug demonstrated reversal of biological aging markers in a new clinical study

Sep 9, 2026

๐Ÿ‡ฎ๐Ÿ‡ณ India

European Equities Slip as Oil Surge Fans Inflation Fear; Novartis Plunges on Drug Trial Setback

The STOXX 600 fell 0.2% as surging oil prices rekindled European inflation concerns, while Novartis plunged after a second drug trial setback and Sandoz gained on long-term growth targets.

Sep 8, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Biotech Company Files for Bankruptcy 11 Weeks Before Pivotal FDA Decision

A biotech files Chapter 11 bankruptcy just 11 weeks ahead of an FDA regulatory decision on its lead drug

Sep 8, 2026

๐Ÿ‡ฎ๐Ÿ‡ณ India

Mounjaro Sales Up 502% as GLP-1 Drugs Reshape India's Pharma Landscape

Mounjaro became India's top-selling pharma brand with โ‚น1,256 crore in MAT sales, a 502% surge year-over-year per PharmaTrac August 2026 data

Sep 8, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Eli Lilly's Acquisition Spree and GLP-1 Leadership Set the Stage for Long-Term Growth

Eli Lilly has been acquiring companies at an accelerated pace, building a pipeline beyond its GLP-1 franchise.

Sep 8, 2026

๐Ÿ‡ฎ๐Ÿ‡ณ India

Sai Life Sciences Near All-Time High: 90%+ Repeat Revenue and CDMO Integration Signal New Growth Phase

Sai Life Sciences is operating near all-time high stock price with over 90% of revenue from repeat customers.

Sep 8, 2026

๐Ÿ‡ฎ๐Ÿ‡ณ India

RPG Life Sciences Targets Bigger API Expansion After โ‚น215 Crore Acquisitions; GLP-1 Launch in October

RPG Life Sciences spent โ‚น215 crore acquiring Actis Generics and Raghava Life Sciences in five weeks, boosting API capacity fivefold to 505 KL.

Sep 8, 2026

๐Ÿ‡จ๐Ÿ‡ฆ Canada

Teva Pharmaceutical Launches EUR and USD Senior Notes Offering Via Dutch Finance Subsidiaries

Teva Pharmaceutical announced plans to issue EUR-denominated and USD-denominated senior notes through its Dutch finance subsidiaries.

Sep 8, 2026

๐Ÿ‡ฐ๐Ÿ‡ท South Korea

Hanmi Pharma Pairs Obesity Drug 'Efe' With Digital Health App to Improve Long-Term Outcomes

Hanmi Pharmaceutical is combining its obesity drug 'Efe' with a smartphone app for integrated patient monitoring

Sep 6, 2026

๐Ÿ‡ฆ๐Ÿ‡บ Australia

WiseTech Global (WTC) and CSL Ltd (CSL): Two ASX Shares to Watch on Valuation and Strategic Momentum

WiseTech Global and CSL emerge as two high-conviction ASX watches, with WTC's CargoWise platform benefiting from freight digitisation and CSL's plasma expansion supporting long-duration biotech growth.

Sep 6, 2026

๐Ÿ‡จ๐Ÿ‡ฆ Canada

Conavi Medical Signs Marketing Deals to Boost Awareness of Cardiovascular Imaging Technology

Conavi Medical (TSXV: CNVI) signed media and digital marketing agreements to increase awareness of its cardiovascular imaging technology platform

Sep 5, 2026

๐Ÿ‡ฉ๐Ÿ‡ช Germany

Danish FSA Exempts Coloplast From Mandatory Takeover as Controlling Stake Moves to Non-Profit Foundation

Denmark's Financial Supervisory Authority granted an exemption from mandatory takeover offer requirements for Coloplast A/S as controlling ownership transfers from NPLH Holding ApS to a non-profit foundation

Sep 5, 2026